A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST)

被引：0
|
作者：
Somaiah, Neeta
Van Tine, Brian Andrew
Chmielowski, Bartosz
Drabick, Joseph J.
Chawla, Sant P.
McKean, Meredith
Spira, Alexander I.
O'Byrne, Kenneth John
Foresto, Steven A.
Movva, Sujana
Kim, AeRang
Gastman, Brian
Pressey, Joseph Gerald
Paudyal, Ben
De, Asit
Winkler, Robert E.
Li, Mingyu
Ahmad, Mohammad
Yang, Dajun
Zhai, Yifan
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Washington Univ St Louis, St Louis, MO USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] Penn State Canc Inst, Hershey, PA USA
[5] Sarcoma Oncol Res Ctr, Santa Monica, CA USA
[6] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[7] Virginia Canc Specialists, Fairfax, VA USA
[8] Princess Alexandra Hosp, Brisbane, Qld, Australia
[9] Queensland Univ Technol, Brisbane, Qld, Australia
[10] Queensland Childrens Hosp, Brisbane, Qld, Australia
[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[12] Childrens Natl Med Ctr, Washington, DC 20010 USA
[13] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[14] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[15] Ascentage Pharma Grp Inc, Rockville, MD USA
[16] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[17] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14627
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MDM2 Amplification in Malignant Peripheral Nerve Sheath Tumors Correlates With p53 Protein Expression
    Wallander, Michelle L.
    Tripp, Sheryl
    Layfield, Lester J.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (01) : 95 - 99
  • [2] A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors
    Zhang, X.
    Wen, X.
    Peng, R.
    Pan, Q.
    Weng, D.
    Ma, Y.
    Zhang, Y.
    Yang, J.
    Men, L.
    Wang, H.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhang, L.
    Zhai, Y.
    ESMO OPEN, 2024, 9 (08)
  • [3] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
    Duncan, SJ
    Cooper, MA
    Williams, DH
    CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
  • [4] Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
    McKean, Meredith
    Tolcher, Anthony W.
    Reeves, James Andrew
    Chmielowski, Bartosz
    Shaheen, Montaser F.
    Beck, Joseph Thaddeus
    Orloff, Marlana M.
    Somaiah, Neeta
    Van Tine, Brian Andrew
    Drabick, Joseph J.
    Spira, Alexander I.
    O'byrne, Kenneth
    Karapetis, Christos Stelios
    Foresto, Steven A.
    Movva, Sujana
    Martinez, Jose
    Li, Mingyu
    Winkler, Robert
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Christine Wasylyk
    Roberto Salvi
    Manuela Argentini
    Christine Dureuil
    Isabelle Delumeau
    Joseph Abecassis
    Laurent Debussche
    Bohdan Wasylyk
    Oncogene, 1999, 18 : 1921 - 1934
  • [6] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    ONCOGENE, 1999, 18 (11) : 1921 - 1934
  • [7] On the biosynthesis of an inhibitor of the p53/MDM2 interaction
    Duncan, SJ
    Williams, DH
    Ainsworth, M
    Martin, S
    Ford, R
    Wrigley, SK
    TETRAHEDRON LETTERS, 2002, 43 (06) : 1075 - 1078
  • [8] MDM2 chaperones the p53 tumor suppressor
    Wawrzynow, Bartosz
    Zylicz, Alicja
    Wallace, Maura
    Hupp, Ted
    Zylicz, Maciej
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (45) : 32603 - 32612
  • [9] MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma
    Wang, Guangfeng
    Liang, Eric
    Tang, Chunyang
    Rui, Li
    Min, Ping
    Lv, Jing
    Ge, Yangfeng
    Zhang, Fei
    Wang, Lvcheng
    Shang, Jingjin
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
    Costa, Barbara
    Bendinelli, Sara
    Gabelloni, Pamela
    Da Pozzo, Eleonora
    Daniele, Simona
    Scatena, Fabrizio
    Vanacore, Renato
    Campiglia, Pietro
    Bertamino, Alessia
    Gomez-Monterrey, Isabel
    Sorriento, Daniela
    Del Giudice, Carmine
    Iaccarino, Guido
    Novellino, Ettore
    Martini, Claudia
    PLOS ONE, 2013, 8 (08):
12345